Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Steven D Leach

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2689-1871; OpenAlex author ID A5028680767; NIH RePORTER profile ID 1899930. Sources: OpenAlex.

Their work

Papers
22 (first author 5, last author 6)
Trials
0
Grants
8
Labs led
3
Collaborators
113
Papers, trials and grants by year

2012: 2 grants · 2013: 1 grant · 2014: 4 papers, 1 grant · 2015: 2 papers, 1 grant · 2016: 1 paper · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers, 1 grant · 2021: 2 papers, 1 grant · 2022: 1 paper, 1 grant · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 22

  1. Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Co-author DOI 10.1016/j.devcel.2026.04.012↗
  2. A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. Co-author DOI 10.1016/j.stem.2023.11.011↗
  3. Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer. First author DOI 10.1016/j.jcmgh.2021.07.014↗
  4. Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Last author DOI 10.1038/s41467-021-23237-2↗
  5. Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies. First author DOI 10.18632/oncotarget.27901↗
  6. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Last author DOI 10.1016/j.ccell.2020.05.010↗
  7. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Last author DOI 10.1073/pnas.1920240117↗
  8. Tumor microtubes connect pancreatic cancer cells in an Arp2/3 complex-dependent manner. Co-author DOI 10.1091/mbc.e19-11-0605↗
  9. ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0529↗
  10. Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter? Co-author DOI 10.1158/1078-0432.ccr-18-3042↗
  11. Zebrafish model of KRAS-initiated pancreatic cancer. First author DOI 10.1080/19768354.2018.1530301↗
  12. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Last author DOI 10.1038/nature24462↗
  13. Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1615↗
  14. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Co-author DOI 10.1158/1078-0432.ccr-17-0162↗
  15. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗
  16. New insights in the development of pancreatic cancer. First author DOI 10.1097/mog.0000000000000295↗
  17. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗
  18. Interleukin interrupted: a new strategy for the treatment of pancreatic cancer. Co-author DOI 10.1084/jem.2123insight1↗
  19. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Last author DOI 10.1053/j.gastro.2013.09.050↗
  20. The tumor suppressor rpl36 restrains KRAS(G12V)-induced pancreatic cancer. Last author DOI 10.1089/zeb.2014.1024↗
  21. Zebrafish reporter lines reveal in vivo signaling pathway activities involved in pancreatic cancer. Co-author DOI 10.1242/dmm.014969↗
  22. Targeting IL-17 for pancreatic cancer prevention. First author DOI 10.18632/oncotarget.2618↗

Grants 8

  1. Developing ATAC-array as a novel epigenetic biomarker to guide personalized therapy in pancreatic cancer R21CA263285↗
  2. Defining neoantigen immunodominance for antigen selection and biomarker discovery in human pancreatic cancer immunotherapy U01CA224175↗
  3. Comprehensive genetic dissection of druggable KRAS targets R01CA204228↗
  4. Eliminating T cell barriers in pancreatic cancer patients AWARD pancan:2015-steven-leach-md-eliminating-t-cell-barriers-in-pancreati
  5. Centroacinar progenitors in mouse and zebrafish pancreas R01DK056211↗
  6. Zebrafish Core P01CA134292↗
  7. Regulation of Exocrine Pancreatic Progenitors by Ptf1a-p48 R01DK061215↗
  8. High resolution and single cell analyses of PanIN initiation and progression R21CA158898↗

Closest collaborators

The 25 strongest of 113 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rohit Chandwani · 5 shared papers, 2020–2026 · strength 0.84
  2. Christine A. Iacobuzio–Donahue · 10 shared papers, 2014–2026 · strength 0.82
  3. Vinod P. Balachandran · 4 shared papers, 1 shared grant, 2017–2021 · strength 0.81
  4. Gökçe Aşkan · 6 shared papers, 2017–2026 · strength 0.55
  5. Adrien Grimont · 2 shared papers, 2022–2026 · strength 0.46
  6. Fong Cheng Pan · 3 shared papers, 2020–2026 · strength 0.46
  7. Olivera Grbovic-Huezo · 4 shared papers, 2017–2020 · strength 0.31
  8. Luisa F. Escobar‐Hoyos · 2 shared papers, 2020–2021 · strength 0.29
  9. Ryan R. Kawalerski · 1 shared paper, 2021 · strength 0.22
  10. S. Sinha · 2 shared papers, 2016–2021 · strength 0.22
  11. Aslihan Yavas · 1 shared paper, 2026 · strength 0.20
  12. Xian Zhang · 1 shared paper, 2026 · strength 0.20
  13. Danwei Huangfu · 1 shared paper, 2026 · strength 0.20
  14. Jen Jen Yeh · 1 shared paper, 2026 · strength 0.20
  15. Peter J. Allen · 3 shared papers, 2017–2020 · strength 0.19
  16. Xiaohua Duan · 1 shared paper, 2024 · strength 0.18
  17. Kenneth H. Yu · 3 shared papers, 2015–2019 · strength 0.17
  18. Joon Tae Park · 1 shared paper, 2018 · strength 0.17
  19. Alvin P. Makohon-Moore · 2 shared papers, 2017–2021 · strength 0.15
  20. Brian T. Herbst · 3 shared papers, 2017 · strength 0.15
  21. Eileen Mary O'Reilly · 2 shared papers, 2017–2019 · strength 0.14
  22. Maeve Aine Lowery · 2 shared papers, 2017–2019 · strength 0.14
  23. Danielle C. Glassman · 2 shared papers, 2017–2021 · strength 0.14
  24. Florencia M. McAllister · 2 shared papers, 2014 · strength 0.13
  25. Anirban Maitra · 1 shared paper, 1 shared grant, 2013–2014 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.